What is PCSA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PCSA?

P/E (TTM) is n/a and 52-week range is $1.04 to $10.25 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PCSA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PCSA?

The company profile lists revenue (TTM) near $81K, net income (TTM) near -$241M, EPS (TTM) near -$5.77 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Processa Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Vero Beach, Florida, US, 2.8M shares outstanding, ISIN US74275C4033 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Processa Pharmaceuticals Inc

$PCSA

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. The company is headquartered in Vero Beach, Florida and currently employs 12 full-time employees. The company went IPO on 2013-10-07. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.

Employees

Website

www.processapharmaceuticals.com/

IPO

2013-10-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US74275C4033

Headquarters

Vero Beach, Florida, US

Shares outstanding

2.8M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

14.91%

Browse other companiesFree AI scores and summaries for more stocks